Determination of a dipeptidyl peptidase IV agonist, β-aminoacyl containing thiazolidine derivatives (KR-66223) in rat plasma by liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 5, 2011, Pages 1083-1088

  Kim, Min Sun ^a   Park, Jong Shik ^a   Jang, Su Min ^a   Lee, Byung Hoi ^a   Ahn, Sung Hoon ^a   Ahn, Jin Hee ^a   Yoo, Sung Eun ^a   Song, Im Sook ^b   Silinski, Peter ^c   Schneider, Stephen Edward ^c   Bae, Myung Ae ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Kainos Medicine USA Inc   (United States)

Author keywords

KR 66223; LC MS MS; Method validation; Pharmacokinetics; Rat plasma

Indexed keywords

ACETONITRILE; AMMONIUM FORMATE; IMIPRAMINE; KR 66223; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CONTROLLED STUDY; DRUG DETERMINATION; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ACETONITRILES; AMINOBUTYRIC ACIDS; ANIMALS; AREA UNDER CURVE; BLOOD PROTEINS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DIPEPTIDYL PEPTIDASE 4; FORMIC ACIDS; IMIPRAMINE; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; THIAZOLIDINES;

EID: 79956139769     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.03.015     Document Type: Article

References (18)

1. The 2007 National Diabetes Fact Sheet, American Diabetes Association (ADA), (2007). http://www.diabetes.org/diabetes-basics/diabetes-statistics.
2. Zimmet P., Alberti K.G.M.M., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
3. Skyler J.S. Diabetes mellitus: pathogenesis and treatment strategies. J. Med. Chem. 2004, 47:4113-4117.
4. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001, 414:821-827.
5. McIntosha C.H.S., Demuthb H., Pospisilika J.A., Pedersona R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. Regul. Pept. 2005, 128:159-165.
6. Kawaguchi M., Okabe T., Terai T., Hanaoka K., Kojima H., Minegishi I., Nagano T. A Time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening. Chem. Eur. J. 2010, 16:13479-13486.
7. Ahn J.H., Park W.S., Jun M.A., Shin M.S., Kang S.K., Kim K.Y., Rhee S.D., Bae M.A., Kim K.R., Kim S.G., Kim S.Y., Sohn S.K., Kang N.S., Lee J.O., Lee D.H., Cheon H.G., Kim S.S. Synthesis and biological evaluation of homopiperazine derivatives with β-aminoacyl group as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:6525-6529.
8. Weber A.E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. 2004, 47:4135-4141.
9. International Publication Number: WO 2008/087560 A2, World Intellectual Property Organization (2008).
10. Park W.S., Kang S.K., Jun M.A., Shin M.S., Kim K.Y., Rhee S.D., Bae M.A., Kim M.S., Kim K.R., Kang N.S., Yoo S.E., Lee J.O., Song D.H., Silinski P., Schneider S.E., Ahn J.H., Kim S.S. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2011, 21:1366-1370.
11. H. J. Ahn, K.B. Kim, K.H. Liu, J.G. Shin, J.H. Ahn, M.S. Kim, M.A. Bae, I.S. Song, In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223, Xenobiotica, in press, doi:10.3109/00498254.2011.552649.
12. Cwika M.J., Wua H., Muzzioa M., McCormicka D.L., Kapetanovicb I. Direct quantitation of glucoraphanin in dog and rat plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 2010, 52:544-549.
13. Wena J., Hong Z., Wua Y., Wei H., Fan G., Wu Y. Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: Application to the pharmacokinetic study in healthy Chinese volunteers. J. Pharm. Biomed. Anal. 2009, 49:347-353.
14. Bhaumik U., Ghosh A., Sarkar A.K., Bose A., Selvan P.S., Sengupta P., Chakraborty U.S., Ghosh D., Kumar Pal T. Determination of ranolazine in human plasma by LC-MS/MS and its application in bioequivalence study. J. Pharm. Biomed. Anal. 2008, 48:1404-1410.
15. Srinivas N.R. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomed. Chromatogr. 2006, 20:383-414.
16. Hopfgartner G., Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom. Rev. 2003, 22:195-214.
17. Kim Y.H., Ji H.Y., Lee S., Yi K.Y., Kim Y.S., Lee K.H., Lee H.S. Determination of a selective Na+/H+ exchanger inhibitor 4-cyano(benzo[b]thiophene-2-carbonyl)guanidine (KR-33028) in rat plasma by liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 2007, 21:810-815.
18. Kitteringhama N.R., Jenkinsa R.E., Laneb C.S., Elliott V.L., Parka B.K. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B 2009, 877:1229-1239.